Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
The Baryon Picture of the Cosmos (ByoPiC)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Universe sciences
Panel description: Astro-physics/-chemistry/-biology; solar system; planetary systems; stellar, galactic and extragalactic astronomy; cosmology; space sciences; astronomical instrumentation and data
Countries involved: France
Call: ERC Advanced Grant (ERC-2015-AdG, 2015)
Start date: 2017-01-01
End date: 2023-06-30
Duration (months): 78.0
Total project cost (EUR): 2488350.0
EU funding (EUR): 2488350.0
Participants: 1
Project status: SIGNED

The cosmological paradigm of structure formation is both extremely successful and plagued by many enigmas. Not only the nature of the main matter component, dark matter, shaping the structure skeleton in the form of a cosmic web, is mysterious; but also half of the ordinary matter (i.e. baryons) at late times of the cosmic history, remains unobserved, or hidden! ByoPiC focuses on this key and currently unresolved issue in astrophysics and cosmology: Where and how are half of the baryons hidden at late times? ByoPiC will answer that central question by detecting, mapping, and assessing the physical properties of hot ionised baryons at large cosmic scales and at late times. This will give a completely new picture of the cosmic web, added to its standard tracers, i.e. galaxies made of cold and dense baryons. To this end, ByoPiC will perform the first statistically consistent, joint analysis of complementary multiwavelength data: Planck observations tracing hot, ionised baryons via the Sunyaev-Zeldovich effect, optimally combined with optical and near infrared galaxy surveys as tracers of cold baryons. This joint analysis will rely on innovative statistical tools to recover all the (cross)information contained in these data in order to detect most of the hidden baryons in cosmic web elements such as (super)clusters and filaments. These newly detected elements will then be assembled to reconstruct the cosmic web as traced by both hot ionised baryons and galaxies. Thanks to that, ByoPiC will perform the most complete and detailed assessment of the census and contribution of hot ionised baryons to the total baryon budget, and identify the main physical processes driving their evolution in the cosmic web. Catalogues of new (super)clusters and filaments, and innovative tools, will be key deliverable products, allowing for an optimal preparation of future surveys.
Building a trusty future food system by using blockchain tech (TrustEat)

Framework: Horizon 2020 — Spreading excellence and widening participation
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Action type: Coordination and support actions
Countries involved: Switzerland,Netherlands,Portugal
Call: Twinning (H2020-WIDESPREAD-2020-5, 2020)
Start date: 2020-10-01
End date: 2023-09-30
Duration (months): 36.0
Total project cost (EUR): 894362.63
EU funding (EUR): 894362.63
Participants: 3
Project status: SIGNED

The TrustEat! project is a Twinning action between the International Iberian Nanotechnology Laboratory (INL, Portugal), Wageningen University & Research (WUR, Netherlands), and IBM Research (Switzerland) in the field of food blockchain. The essence of the partnership is to strengthen the research area of food blockchain, focusing on improving INL´s research profile and capturing future opportunities of joint research. With these objectives, partners will develop a R&D Strategic Roadmap, will conduct training for senior and junior researchers, benchmark activities in research management and develop different activities with stakeholders to make the project sustainable, facilitating the transfer of knowledge. Activities include staff exchanges, expert visits, on-site/virtual training, workshops, conference, joint summer schools and activities to increase the ecosystem awareness. Food safety is a basis for effective functioning of markets with trust and transparency. Food safety risks occur along the food chain from a number of contaminants. In addition, malpractices or fraudulent practices could also lead to increased food safety risks. It is of major importance for the public health to develop integrated approaches along the entire food chain for detecting, assessing, and mitigating pathogens and contaminant hazards. The food blockchain technology would allow to ensure the food value chain integrity to consumers, that is, safety, traceability and authenticity. By using blockchain all the stakeholders in the food value chain will know where their food comes in real-time data, which can really increase trust and confidence about food production from start to finish. By establishing a link between two of the best leading institutions in food integrity and blockchain, INL will improve the quality and the innovative nature of the developed research, will strengthen the interaction of partners, taking the research to the next level.

Keywords: food integrity,blockchain,traceability,authenticity
Tagged (DIVA) polyantigenic vaccine against Bovine Viral Diarrhea virus (BVDv) based on virus-Like-Particles (BoVLP-BVD)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Spain
Call: SME instrument (H2020-SMEInst-2018-2020-2, 2019)
Start date: 2019-05-01
End date: 2022-01-31
Duration (months): 33.0
Total project cost (EUR): 2221042.5
EU funding (EUR): 1554729.75
Participants: 1
Project status: CLOSED

In a general context of environmental, social and legal pressure to reduce the use of antibiotics to fight diseases in livestock animals, cost-effective vaccination becomes the focus of most of the industry, regulatory and agro-food public bodies. Development of new vaccines to prevent the disease and therefore avoid the use of antibiotics or to improve suboptimal available vaccines is now an European and industry priority. Bovine viral diarrhea virus (BVDV) is an important infectious agent of cattle worldwide that affects herd productivity and reproduction. BVD has been and is an endemic disease in all countries where no systematic eradication and control programs have been established. Under these conditions, approximately 50% of the herds have or have had animals with persistent infection, and approximately 90% of the cattle have been exposed to the virus at some point during their lifetime. Infection with BVDV has a major economic impact, estimated in hundreds of euros per animal for a European hut of around 80 million animals. Aquilón CyL, a leading biotech company, has developed new recombinant vaccine against BVDV using a Virus-Like- Particle patented technology. Aquilón has demonstrated the technical, commercial and regulatory feasibility by the SME instrument phase 1 project (nº 774994). After developing the vaccine to TRL6 stage (pre-industrial prototype with positive activity data), Aquilón will develop one vaccine to TRL8 stage, demonstrating the commercial-scale manufacturing and in-vivo safety, efficacy and DIVA attributes in the target species. This vaccine candidate will be licensed to one or more veterinarian pharmaceutical company that will complete the final field studies required for commercialisation. Our business projections, based on agreements with Development milestones and commercial royalties, show potential for a 5X investment multiplier with a 25% internal rate of return.

Keywords: antibiotic free,virus like particle,bovine viral diarrhea,bvdv,recombinant,vaccine,diva,lifestock,bovine vaccine,cattle,respiratory disease,reproductive disease
demonstRation of EU effective lArge sCale tHreat and crIsis maNaGement OUTside the EU (Reaching out)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure societies - protecting freedom and security of Europe and its citizens
Action type: Innovation actions
Countries involved: Germany,Italy,Italy,Spain,Israel,Austria,Estonia,Italy,Italy,Norway,Belgium,Sweden,Poland,Finland,France,France,France,France,France,France,France,United Kingdom,United Kingdom,Luxembourg,United Kingdom
Call: Crisis management topic 3: Demonstration activity on large scale disasters and crisis management and resilience of EU external assets against major identified threats or causes of crisis (H2020-DRS-2015, 2015)
Start date: 2016-10-01
End date: 2019-11-30
Duration (months): 38.0
Total project cost (EUR): 21101721.25
EU funding (EUR): 18811558.38
Participants: 28
Project status: CLOSED

Effective EU support to a large external crisis requires new approaches. In response to this challenge and to identified user and market needs from previous projects, Reaching Out proposes an innovative multi-disciplinary approach that will optimize the efforts, address a wide spectrum of users and maximize market innovation success. This approach results in five main objectives: to 1. Develop a Collaborative Framework, with distributed platforms of functional services, 2. Implement a flexible and open “collaborative innovation” process involving users and SMEs, suppliers, operators and research organisations, 3. Develop, upgrade and integrate 78 new connectable and interoperable tools, 4. Conduct 5 large scale demonstrations on the field: o health disaster in Africa (Epidemics in Guinea, with strong social and cultural issues), o natural disaster in a politically complex region and a desert environment (Earthquake in the Jordan Valley, led jointly by Jordan, Israel and Palestine), o three global change disasters in Asia targeted at large evacuation and humanitarian support in Bangladesh (long lasting floods, huge storms and associated epidemics,), EU citizen support and repatriation in Shanghai (floods & storm surge), radiological and industrial disasters impacting EU assets in Taiwan (flash floods, landslides, storm surge and chemical and radiological disasters), supported and co-funded by local authorities, 5. Provide recommendations and evaluations for future legal and policy innovations. The project will be conducted under the supervision of senior end-users. It will be performed with flexible and proven procedures by a balanced consortium of users, industry, innovative SMEs, RTO and academia in the EU and the demonstration regions. The main expected impact is to improve external disaster and crisis management efficiency and cost-benefit and increase the EU visibility whilst enhancing EU industry competitiveness and enlarging the market.

Keywords: external disaster preparedness response market
Unraveling changes in cellular gene expression during viral infection (Profile Infection)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Immunity, Infection and Immunotherapy
Panel description: The immune system, related disorders and their mechanisms, biology of infectious agents and infection, biological basis of prevention and treatment of infectious diseases, innovative immunological tools and approaches, including therapies
Countries involved: Israel
Call: ERC Starting Grant (ERC-2014-STG, 2014)
Start date: 2015-06-01
End date: 2020-05-31
Duration (months): 60.0
Total project cost (EUR): 1500000.0
EU funding (EUR): 1500000.0
Participants: 1
Project status: CLOSED

The herpesvirus human cytomegalovirus (HCMV) infects the majority of the world's population, leading to severe diseases in millions of newborns and immunocompromised adults annually. During infection, HCMV extensively manipulates cellular gene expression to maintain conditions favorable for efficient viral propagation. Identifying the pathways that the virus relies on or subverts is of great interest as they have the potential to provide new therapeutic windows and reveal novel principles in cell biology. Over the past years high-throughput analyses have profoundly broadened our understanding of the processes that occur during HCMV infection. However, much of this analysis is focused on transcriptional changes at the lytic phase of infection leaving posttranscriptional regulation and the latent phase of the virus relatively untouched. Novel emerging technologies have the potential to extend our knowledge in areas that were heretofore unattainable. My overall goal is to decipher the multiple mechanisms by which HCMV modulates the host cell. For this, I will use multiple cutting-edge deep-sequencing and imaging technologies that will allow the analysis of novel aspects of host gene regulation during infection. Accordingly, the primary objectives of this research proposal are: 1) Deciphering posttranscriptional mechanisms that control cellular gene expression during HCMV infection; 2) Identifying and characterizing cellular protein diversification during infection; and 3) Uncovering the changes that occur in infected cells during latent infection. The knowledge generated from these objectives will provide us with a clearer depiction of the changes that take place during HCMV infection, which in turn can facilitate the development of novel anti-viral strategies. More broadly, with its comprehensive and complementarity approaches, this work will provide a paradigm for understanding how gene expression is regulated during a complex biological process.

Keywords: translation,cytomegalovirus,posttranscriptional regulation
Preparation for the establishment of a European SST Service provision function (PASS)

Framework: Horizon 2020 — Industrial Leadership
Programme: Space
Action type: Coordination and support actions
Countries involved: Spain
Call: SPACE (H2020-Adhoc-2014-20, 2014)
Start date: 2014-09-01
End date: 2016-12-31
Duration (months): 28.0
Total project cost (EUR): 1153250.0
EU funding (EUR): 1000000.0
Participants: 1
Project status: CLOSED

The protection of European space infrastructures including the setting up of a Space Surveillance and Tracking (SST) capability at European level, represents a new priority of the EU space policy. The H2020 Work Programme for Space 2014-15 addresses challenges associated with this programmatic priority and ensures adequate support to the relative topics and actions. The main initiative towards the development of a SST capability at European level is represented by the SST Support Framework decision adopted by the Council and the European Parliament on the 16 of April 2014. The European Union Satellite Centre (EU SatCen) is an EU Agency linking space and security and with long experience in delivering geospatial imagery information services and products with various levels of classification to both civil and defence users. Its expertise in handling confidential information in a secure environment and its tight institutional links with the Member States has enabled the EU SatCen to build distinctive expertise on SST issues. The PASS (Preparation for the establishment of a European SST Service provision function) support action will aim at ensuring the transition of the EU SatCen SSA activities towards the Centre’s contribution to the setup of a SST service provision function within the SST Support Framework initiative by identifying necessary functional elements and interfaces with relevant SST actors, with particular emphasis on security aspects. PASS will strive to propose mature definitions of such interfaces, benefiting from the fruitful collaboration already established with the main actors involved. It will provide a technical contribution to this objective and to the future establishment of the SST capability by developing a representative SST service provision function pilot. Moreover, PASS will also contribute in exploring the different contexts and scenarios for the cooperation of the EU SatCen within the SST Support Framework

Keywords: space surveillance and tracking,space policy,data policy,operational interfaces,space and security,sst support framework
Modeling the Gravitational Spectrum of Neutron Star Binaries (BinGraSp)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Fundamental constituents of matter
Panel description: Particle, nuclear, plasma, atomic, molecular, gas, and optical physics
Countries involved: Germany,Italy,Italy
Call: ERC Starting Grant (ERC-2016-STG, 2016)
Start date: 2017-10-01
End date: 2022-09-30
Duration (months): 60.0
Total project cost (EUR): 1432301.0
EU funding (EUR): 1432301.0
Participants: 3
Project status: CLOSED

The most energetic electromagnetic phenomena in the Universe are believed to be powered by the collision of two neutron stars, the smallest and densest stars on which surface gravity is about 2 billion times stronger than gravity on Earth. However, a definitive identification of neutron star mergers as central engines for short-gamma-ray bursts and kilonovae transients is possible only by direct gravitational-wave observations. The latter provide us with unique information on neutron stars' masses, radii, and spins, including the possibility to set the strongest observational constraints on the unknown equation-of-state of matter at supranuclear densities. Neutron stars binary mergers are among the main targets for ground-based gravitational-wave interferometers like Advanced LIGO and Virgo, which start operations this year. The astrophysical data analysis of the signals emitted by these sources requires the availability of accurate waveform models, which are missing to date. Hence, the theoretical understanding of the gravitational spectrum is a necessary and urgent step for the development of a gravitational-based astrophysics in the next years. This project aims at developing, for the first time, a precise theoretical model for the complete gravitational spectrum of neutron star binaries, including the merger and postmerger stages of the coalescence process. Building on the PI's unique expertise and track record, the proposed research exploits synergy between analytical and numerical methods in General Relativity. Results from state of the art nonlinear 3D numerical relativity simulations will be combined with the most advanced analytical framework for the relativistic two-body problem. The model developed here will be used in the first gravitational-wave observations and will dramatically impact multimessenger astrophysics.

Keywords: gravitational waves,numerical relativity,binary neutron stars
QUantitative Imaging Biomarkers Medice (QUIBIM)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: SME instrument
Countries involved: Spain
Call: Open Disruptive Innovation Scheme (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-08-01
End date: 2016-12-31
Duration (months): 5.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

QUIBIM Precision® is the first imaging biomarkers analysis platform in the cloud presenting innovative whilst extremely useful characteristics for the sector: 1) Automated analysis of imaging biomarkers (results are ready just within minutes) with the best accuracy and reproducibility; 2) Medically certified: QUIBIM are medically valid to scientifically support decision making; 3) Open to any physicians: Optimized User Interface (UI), user experience (UX) and imaging analysis functionalities 4) Cost-effective: QUIBIM helps reduce costs of medical testing and misdiagnosis, especially from specialists as each report costs 45€. QUIBIM allows any physician to make more accurate diagnosis by providing additional information extracted from the same imaging sample (tomography, radiology…) already acquired. Our technology based on machine learning and image processing algorithms scout the image and compare it to similar images in our database with known ground-truth diagnosis, based on patterns not obvious to a human eye. Regarding out target market: According to WHO , the total supply of physicians worldwide is estimated in 12,7 million. Our priority markets, America and Europe, accounts for 65% (8,26 million physicians) and present the highest level of health expenditure in the world. Within physicians, 43% are General Practitioners and 57% are specialists . Considering specialists, only, the resulting target market size is 4,70 million specialists. We forecast to generate revenues above €40 million in the 5th year of sales. In terms of employment, we expect to generate a minimum of 80 jobs (+120 to 180 indirect) by that same year. For Phase 2 we estimate a total budget of 1 Million Euros in 20 months. After this stage, private investment will be negotiated (Phase 3). We aim to bring the final version of QUIBIM quickly (end of Phase 2: 2018).

Keywords: business innovation,disruption,blue ocean,business plan,high growth
Cell therapy for patients with chronic heart failure with proprietary cardiac-derived cells (CardAP cells) – “From the Heart to the Heart” (CardAPcells)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Germany
Call: Supporting innovative SMEs in the healthcare biotechnology sector (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-07-01
End date: 2016-12-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Chronic heart failure is a life-threatening disease usually without cure and a leading cause of morbidity and mortality. In Germany 45 000 patients (projected to EU: about 140 000) die every year from progressive chronic cardiac insufficiency. There is no curative therapeutic solution, except very rare donor hearts and artificial hearts as bridge devices. Researchers at the Charité - University Medicine, have identified unique cardiac-specific stromal cells (CardAP cells) with strong efficacy in cardiac stress models. CardAP cells are specialized heart-derived cells with key advantages in safety and efficacy. CardAP cells fulfil all criteria for cardiac cell therapy and cell product manufacturing has been transferred to GMP facilities. CellServe, a Charité spin off, will develop the CardAP cells for therapy of patients suffering from severe life-threatening cardiomyopathy. CellServe has acquired an exclusive license of this technology and will perform a clinical phase I/II study for patients with chronic cardiomyopathy. The technology of CellServe is completely distinct from all competitors, using specialized stromal heart cells and not stem cells. CellServe has an experienced management in cell-based therapies area to develop and market ATMP products. It will apply for a so-called hospital exemption regulation, a limited preliminary approval, for early market introduction directly after the clinical study. Commercial potential: Worldwide 22 Mio people suffer from chronic cardiac insufficiency. In Phase 1 a business plan for the CardAP cell product will be generated including financial calculations and the preparations for the clinical study will be finalised. Achievements Phase 2: • Phase I/II clinical trial • Approval for Hospital Exemption for ATMPs • Preparation of a multicenter clinical trial • Fulfilment of all regulatory requirements to perform a phase III clinical study • Equity financing

Keywords: cardiomyopathy,cardapcells,cell therapy,atmp,clinical study